Leerink Partners analyst Puneet Souda has maintained their bullish stance on RVTY stock, giving a Buy rating yesterday.
Puneet Souda has given his Buy rating due to a combination of factors that highlight Revvity’s resilience amidst macroeconomic uncertainties. The company’s diversified portfolio, particularly its strengths in diagnostics and software, helps counterbalance weaknesses in the life sciences segment. This strategic positioning allows Revvity to maintain its organizational growth and earnings per share guidance despite challenging market conditions.
Furthermore, Revvity’s proactive approach to mitigating tariff impacts, especially between the US and China, sets it apart from its peers. The company has effectively managed supply chain adjustments and other mitigation strategies to offset the majority of the tariff impact. This operational flexibility, particularly in life sciences products, alongside a stable pharmaceutical revenue stream, supports the positive outlook and reinforces the Buy rating.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $135.00 price target.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RVTY in relation to earlier this year.